Every letter we have printed

Escalation above the studied ceiling is extrapolation into a region where the dose-response curve is not described. Your piece says this without moralising, which is the right tone, and the sentence that matters is that adverse effects continue to rise where benefit has flattened.

Trace metals catalyse oxidation at concentrations far below anything a specification would flag. It is a plausible explanation for lot-to-lot variation that has nothing to do with the synthesis and everything to do with the water.

Deamidation is the pathway with the best-characterised kinetics and the least presence in popular discussion, presumably because the product has the same mass. It is invisible to the identity check most people rely on.

A short observation. Where an indicator has tripped, most buyers do not ask for a replacement because they assume the material is probably fine. They may well be right, and the effect is that the supplier receives no signal at all.

In-use figures quoted in this market trace back, when you follow them, to manufacturer statements about a different formulation of a different product. The chain of citation is worth publishing on its own.

Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?

You describe orthogonality as insurance against co-elution. It is also insurance against a column that has quietly stopped working. A second method on a second instrument catches the systematic failure that a repeat injection on the first one cannot, and that is the more common failure in a busy laboratory.

The economic point is missing from your analysis. A second orthogonal determination roughly doubles the cost of knowing, and the buyers in this market are mostly individuals paying out of pocket. Recommending it without saying what it costs is the kind of advice that gets ignored rather than argued with.

You might state plainly that absorbance at the peptide bond is not uniform across sequences either. Two impurities present at the same molar concentration will give different areas if one carries an extra tryptophan, and at 214 nanometres the backbone dominates but does not monopolise. Area per cent is an approximation twice over.

The comparison your readers want is between an excursion and the stability data that would justify tolerating it. Without accelerated stability figures for the specific formulation, an excursion assessment is judgement dressed as calculation. Very few suppliers in this trade hold those figures.

Mean kinetic temperature is widely misused as an averaging trick that makes an excursion disappear. It is a weighted mean designed to reflect the Arrhenius relation, and it is a legitimate tool for a whole storage period. Applying it to a single shipment to argue that a two-day excursion averaged out is not what it is for.

Ask which indicator and at what threshold. There are several products with very different trigger conditions and the carton usually says only that one is present.

Dispatch day matters more than packaging. A parcel posted on a Thursday afternoon spends the weekend in a depot, and no amount of insulation is specified for that. Ask what day a shipment leaves, and if the answer is late in the week, ask them to hold it.

Your suggestion of a published lookup at the testing laboratory is the right answer and it is not a large piece of engineering. Report number in, issued or not issued out, with no further detail. It would end the recycled-document trade in the wider market without exposing any customer data at all.

I would add that a genuine chromatogram is far harder to fabricate than a summary page, which is why the summary page is what circulates. A seller who attaches the instrument output is telling you something about their confidence before you read a single number on it.

I would like the trade to adopt a convention on significant figures. A specification of not less than 98 per cent and a result of 98.04 per cent are a pass by two hundredths of a point, which is well inside the repeatability of the method. The certificate should carry the method repeatability alongside the limit, or the pass means nothing.

Residual solvent and counter-ion content are the other two systematic absences, and they interact with the first. A trifluoroacetate salt can carry a substantial mass fraction that is neither peptide nor water, and a buyer weighing the vial contents is weighing all three.

Turnover markers are cheaper, faster and more responsive than imaging, and they are collected in a minority of these studies. They answer a different question and they answer it inside a trial horizon.

Regional and total measurements behave differently and are reported interchangeably. A total figure can be stable while a regional one moves substantially, and both are described as bone density.

I am sixty-eight, I have lost nineteen kilograms over fourteen months, and my consultant has twice told me my lean mass is fine on the basis of a handheld bioimpedance device in the clinic corridor. Having read your piece on what that device measures, I am no longer sure what I have been reassured about.

My mother is eighty-one and on a low dose for her diabetes. Her weight is down nine kilograms and she now struggles to get out of a low chair, which she did not eighteen months ago. Nobody has measured anything. I do not know whether this is the drug, the weight loss, or being eighty-one, and neither does anybody I have asked.

Extrapolating a composition ratio to a different rate of loss is the error I see most often. The relationship is not linear in any dataset I have read, and applying a percentage from a slow-loss cohort to a fast-loss one has no support at all.

Injection site affects absorption for compounds of this kind, and the effect size is published for some of them. It is one of the few practical variables with actual data behind it and it is discussed less than several with none.

Exposure varies several-fold between individuals at the same nominal input, which means any statement relating a dose to an effect is a statement about a population average. The variability is published and rarely quoted.

Long-term receptor pharmacology is genuinely unknown territory, and the honest statement is that the exposure durations now being contemplated exceed the durations that have been studied. That is not alarming and it is not nothing, and it should be said in both those registers at once.

In-use stability is where the real losses happen and where there is least data. A dry powder is forgiving; the same peptide in solution at room temperature is not. Every practical question a buyer has begins at the moment the diluent goes in, and the documentation stops at the moment before.

Nobody measures what they have after storage, which is the only way any of this would be settled. A determination on a solution held for four weeks would produce more information than every discussion thread on the subject combined.

Loggers have become cheap enough that a supplier could include one in every carton for the cost of the outer box. The barrier is the willingness to generate a record that might be unflattering.

I asked a supplier for the shipping validation behind their stated pack and received a two-page summary with a temperature profile and a duration. It took four days. The document existed the whole time and nobody had ever requested it, which is the pattern your reporting keeps finding.

Adsorption to the container is under-appreciated. At low concentrations a meaningful fraction of peptide can be lost to the glass or the plastic within hours, which looks exactly like degradation and is not. It is also the reason a dilute working solution behaves worse than a concentrated one.

I asked four suppliers about this last year and all four answered plainly that it is not part of the standard panel and can be quoted separately. The silence is on the storefront rather than in the correspondence.

A publication that keeps naming what is missing is doing something that cannot be done by a certificate, however good. The list of absent tests is editorial work rather than analytical work.

Particulate matter deserves its own paragraph. Glass delamination, stopper fragments and fibres are all real findings in vialled products, and the only examination most buyers perform is a glance at a powder they cannot see through. Look again after reconstitution and against a dark background.

The lyophilisation step is sometimes described as though it sterilised the material. It does not; it removes water, and organisms and their fragments survive it routinely.

The archive is the asset. Being able to follow one question across three years of issues is a different experience from reading any single piece, and very few publications make it possible.

The point your piece makes about documentation applies to custody with more force. A supplier that publishes its own handling record gives a buyer something to check; a supplier that publishes only a result gives them something to believe.

Photographs are a poor substitute for a signature and a good substitute for nothing. Vial, label, seal, packaging, with a timestamp — five minutes of work that has settled every dispute I have been involved in.

For a small buyer the arithmetic is brutal. Testing a vial can cost a meaningful fraction of what the vial cost, which is why individuals do not test and why the published record is dominated by sellers and by publications like yours. The evidence base has a wealth filter on it.

Your suggestion that laboratories publish the fact of a submission while keeping the result confidential is the first proposal I have read in this area that a laboratory could actually implement without breaching a client obligation. I have raised it internally.

I administer a small purchasing budget and I have stopped treating marks of this kind as evidence at all. Not because they are dishonest, but because I cannot tell from the mark which of the honest cases I am looking at, and a signal I cannot decode is not a signal.